US FDA declines to approve Camurus' rare hormone disorder drug
Oct 22 (Reuters) -The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday.
WHY IT'S IMPORTANT
The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of every 100,000 people.
KEY QUOTE
The decision is "disappointing, however, we are confident in the data supporting our NDA and the potential of CAM2029 to address unmet medical needs of patients with acromegaly," Camurus CEO Fredrik Tiberg said.
MARKET REACTION
Camurus' shares plummeted by 10% in Stockholm trade following the decision.
WHAT'S NEXT
The manufacturing issues could delay the approval of Oclaiz for six months to one year, pushing its launch to the fourth quarter of 2025, according to Jefferies analysts.
Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
